09 April 2008
Update on topical pain relief project
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, can provide the following update on its topical pain relief project, TPR100, using Futura's proprietary trans-dermal delivery technology, DermaSys®.
Completion of clinical studies to evaluate drug delivery using Futura's Dermasys ® technology has been extended to complete formulation optimisation. Commercial negotiations are continuing on a non-exclusive basis.
We will provide further updates to shareholders at the earliest opportunity.
For any further information please contact:
Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.co.uk
www.futuramedical.co.uk
Nominated Adviser:
Canaccord Adams
Ryan Gaffney / Adria Da Breo Richards
Tel: +44 (0) 20 7050 6500
For any media enquiries please contact:
Buchanan Communications Limited
Mark Court
markc@buchanan.uk.com
Rebecca Skye Dietrich
rebeccad@buchanan.uk.com
+44 (0) 20 7466 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.